GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxxinity Inc (OTCPK:VAXX) » Definitions » Operating Cash Flow per Share

Vaxxinity (Vaxxinity) Operating Cash Flow per Share : $-0.45 (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Vaxxinity Operating Cash Flow per Share?

Vaxxinity's operating cash flow per share for the three months ended in Dec. 2023 was $-0.09. Vaxxinity's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.45.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -18.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Vaxxinity's Operating Cash Flow per Share or its related term are showing as below:

VAXX' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -65.5   Med: -41.95   Max: -18.4
Current: -18.4

During the past 5 years, Vaxxinity's highest 3-Year average Operating Cash Flow per Share Growth Rate was -18.40% per year. The lowest was -65.50% per year. And the median was -41.95% per year.

VAXX's 3-Year OCF Growth Rate is ranked worse than
73.36% of 1235 companies
in the Biotechnology industry
Industry Median: 3.3 vs VAXX: -18.40

Vaxxinity Operating Cash Flow per Share Historical Data

The historical data trend for Vaxxinity's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaxxinity Operating Cash Flow per Share Chart

Vaxxinity Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Operating Cash Flow per Share
-0.10 -0.27 -1.06 -0.44 -0.45

Vaxxinity Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Operating Cash Flow per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.12 -0.16 -0.10 -0.10 -0.09

Competitive Comparison of Vaxxinity's Operating Cash Flow per Share

For the Biotechnology subindustry, Vaxxinity's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vaxxinity's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vaxxinity's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Vaxxinity's Price-to-Operating-Cash-Flow falls into.



Vaxxinity Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Vaxxinity's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )=Cash Flow from Operations (A: Dec. 2023 )/Shares Outstanding (Diluted Average) (A: Dec. 2023 )
=-57.238/126.509
=-0.45

Vaxxinity's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Dec. 2023 )=Cash Flow from Operations (Q: Dec. 2023 )/Shares Outstanding (Diluted Average) (Q: Dec. 2023 )
=-11.845/127.218
=-0.09

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vaxxinity Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Vaxxinity's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Vaxxinity (Vaxxinity) Business Description

Industry
Traded in Other Exchanges
N/A
Address
505 Odyssey Way, Merritt Island, FL, USA, 32953
Vaxxinity Inc is engaged in the development and commercialization of prophylactic and therapeutic vaccines to combat chronic disorders and infectious diseases with large patient populations and unmet medical needs. Its pipeline primarily consists of five programs focused on chronic disease, particularly neurodegenerative disorders, in addition to other neurology and cardiovascular indications.
Executives
Sumita Ray officer: Chief Legal Officer, Secretary C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Prime Movers Lab Fund I Lp 10 percent owner P.O. BOX 12829, JACKSON WY 83002
Landon E Ogilvie director 505 ODYSSEY WAY, EXPLORATION PARK FL 32953
Katherine A. Eade director C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD #10, HOLLISTON MA 01746
James Alan Smith director 505 ODYSSEY WAY, EXPLORATION PARK FL 32953
Gabrielle B Toledano director 209 REDWOOD SHORES PARKWAY, REDWOOD CITY CA 94065
Lou Reese director, officer: Executive Chairman C/O VAXXINITY, INC., 1717 MAIN ST STE. 3388, DALLAS TX 75201
Mei Mei Hu director, 10 percent owner, officer: See Remarks C/O VAXXINITY, INC., 1717 MAIN ST STE. 3388, DALLAS TX 75201
United Biomedical Inc 10 percent owner 25 DAVIDS DR, HAUPPAUGE NY 11788
Dakin Sloss 10 percent owner 126 E 56TH ST, 30TH FLOOR, NEW YORK NY 10022
Peter Powchik director REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Jason Pesile officer: See Remarks C/O VAXXINITY, INC., 1717 MAIN ST. STE.3388, DALLAS TX 75201
George R Hornig director 625 MADISON AVE SUITE 10-B, NEW YORK NY 10017
James Chui director C/O VAXXINITY, INC., 1717 MAIN ST STE. 3388, DALLAS TX 75201
Peter Diamandis director 4640 ADMIRALTY WAY, SUITE 500, MARINA DEL REY CA 90292